ArticleAnnals of surgical oncology2026
Robotic Pancreatectomy as an Adjunct to Radical Gastrectomy for Advanced Gastric Cancer: Surgical and Clinical Implications.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe integration of robotic pancreatectomy into radical resections for advanced gastric cancer (AGC) is a novel and underexplored area, offering potential benefits for both patient outcomes and healthcare systems.
methodsIn the first case, a 75-year-old woman with gastric outlet obstruction due to advanced gastric cancer underwent gastric bypass followed by four cycles of neoadjuvant SOX plus trastuzumab. Robotic pancreaticoduodenectomy was subsequently performed alongside distal gastrectomy with D2 lymphadenectomy, addressing pancreatic head invasion. Postoperative recovery was uneventful, with minimal pain and early resumption of oral intake. She remains disease-free 21 months after treatment.
resultsThe second case involved a 66-year-old woman diagnosed with upper gastric cancer with pancreatic body invasion. After achieving a favorable response to four cycles of SOX plus nivolumab, she underwent robotic distal pancreatectomy along with total gastrectomy. Her recovery was smooth, enabling the seamless initiation of adjuvant therapy. She remains recurrence-free 24 months posttreatment.
conclusionsThese cases underscore the advantages of a fully robotic approach, including enhanced surgical precision, faster recovery, and preserved quality of life.
Indexed as
Identifiers
41296231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.